Clinical study of the regimen of combination nedaplain and docetaxel chemotherapy in the treatment for advanced non-small cell lung cancer

Objective:To investigate the efficacy and side effects of the regimen of combined chemotherapy nedaplatin and docetaxel in the treatment of advanced non-small cell lung cancer.Methods:A total of 78 patients with advanced non-small cell lung cancer diagnosed by the pathology and/or cytology were divided into the nedaplatin group(treatment group,n=40)and cisplatin group(control group,n=38).Nedaplatin was given at 80mg/m2 intravenously at the first day in the treatment group.Cisplatin was administrated at 25mg/m2 intravenously for three days in the control group.Docetaxel was infused at 75mg/m2 intravenously at the first day in both groups.A course of treatment included 28 days in both groups.Results:The efficacy of treatment group was 37.5% and control group was 42.1% without significant statistically difference between the two groups(P0.05).A lower response rate of digestive reaction(anorexia 22.5%,nausea and vomiting 15.0%)occurred in treatment group,compared to the control group(anorexia 36.8%,nausea and vomiting 50.0%),with a significant difference between the two groups(P0.05).Hepatotoxicity between two groups was not different but nephrotoxicity of treatment group lowered to control group(7.5% and 23.7%,P=0.05).No difference between two groups in the incidence of leucopenia(37.5% and 39.5%,P0.05)and response rate of anemia(47.5% and 52.6%,P0.05)was found.There was a higher thrombocytopenia response rate in treatment group(47.5%)than in control group(23.7%)with a significant difference between the groups(P0.05).Conclusion:There is no significant difference of response rate between nedaplatin and cisplatin regimens,but there are a lower digestive reaction and nephrotoxicity response rate in nedaplatin group.The thrombocytopenia response rate is higher in treatment group but anemia and leucopenia are not different.Nedaplatin is easy to be accepted by patients and doctors.